These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31893563)

  • 1. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels.
    Manouchehrinia A; Piehl F; Hillert J; Kuhle J; Alfredsson L; Olsson T; Kockum I
    Ann Clin Transl Neurol; 2020 Jan; 7(1):139-143. PubMed ID: 31893563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    J Neuroinflammation; 2018 Jul; 15(1):209. PubMed ID: 30021640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between ANT1 and NFL with autophagy and mitophagy markers in patients with multiple sclerosis.
    Hassanpour M; Cheraghi O; Laghusi D; Nouri M; Panahi Y
    J Clin Neurosci; 2020 Aug; 78():307-312. PubMed ID: 32376155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
    Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
    Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.
    Kuhle J; Barro C; Andreasson U; Derfuss T; Lindberg R; Sandelius Å; Liman V; Norgren N; Blennow K; Zetterberg H
    Clin Chem Lab Med; 2016 Oct; 54(10):1655-61. PubMed ID: 27071153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis.
    Monreal E; Ruiz PD; San Román IL; Rodríguez-Antigüedad A; Moya-Molina MÁ; Álvarez A; García-Arcelay E; Maurino J; Shepherd J; Cabrera ÁP; Villar LM
    Front Public Health; 2024; 12():1397845. PubMed ID: 38711771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain in the assessment of patients with multiple sclerosis.
    Domingues RB; Fernandes GBP; Leite FBVM; Senne C
    Arq Neuropsiquiatr; 2019 Jul; 77(6):436-441. PubMed ID: 31314847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
    McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
    J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients.
    Sejbaek T; Nielsen HH; Penner N; Plavina T; Mendoza JP; Martin NA; Elkjaer ML; Ravnborg MH; Illes Z
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1324-1330. PubMed ID: 31611264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood.
    Hendricks R; Baker D; Brumm J; Davancaze T; Harp C; Herman A; Büdingen HV; Townsend M; Fischer SK
    Bioanalysis; 2019 Aug; 11(15):1405-1418. PubMed ID: 31401845
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
    Neurology; 2017 Nov; 89(22):2230-2237. PubMed ID: 29079686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis.
    Wang SY; Chen W; Xu W; Li JQ; Hou XH; Ou YN; Yu JT; Tan L
    J Alzheimers Dis; 2019; 72(4):1353-1361. PubMed ID: 31744001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament light chain as a biomarker in neurological disorders.
    Gaetani L; Blennow K; Calabresi P; Di Filippo M; Parnetti L; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):870-881. PubMed ID: 30967444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head comparison of four plasma neurofilament light chain (NfL) immunoassays.
    Ashrafzadeh-Kian S; Figdore D; Larson B; Deters R; Abou-Diwan C; Bornhorst J; Algeciras-Schimnich A
    Clin Chim Acta; 2024 Jul; 561():119817. PubMed ID: 38879065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can CSF biomarkers predict future MS disease activity and severity?
    Magliozzi R; Cross AH
    Mult Scler; 2020 Apr; 26(5):582-590. PubMed ID: 31965889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease.
    Peng L; Bi C; Xia D; Mao L; Qian H
    Mult Scler Relat Disord; 2019 May; 30():123-128. PubMed ID: 30771578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3.
    Li QF; Dong Y; Yang L; Xie JJ; Ma Y; Du YC; Cheng HL; Ni W; Wu ZY
    Mol Neurodegener; 2019 Nov; 14(1):39. PubMed ID: 31684998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.